Citius Oncology, Inc. (CTOR) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $1.14 (+11.76%), Market cap $0.08B, 52-week low–high $0.49 ~ $5.29.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Financial statements, price targets, institutional (13F) holdings and related news for Citius Oncology, Inc. are updated in real time on BlackAll Trade.
Citius Oncology, Inc. trades at $1.14 (+11.76%). Real-time quotes and charts are available on BlackAll Trade.
Citius Oncology, Inc. has a market cap of about $0.08B.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment